Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma

Table 5 Belinostat and metabolite plasma parameters—PK population (N = 9)

PK Parameters (units)	Belinostat	Belinostat Glucuronide	Belinostat Acid	Belinostat Amide	Methyl Belinostat	3-ASBA
PK Parameters (units)	Mean ± Standard Deviation N = 9
C_max (ng/mL)	36,300 ± 9320	163,000 ± 19,200	1030 ± 638	2850 ± 869	7030 ± 1270	2660 ± 1530
T_max^a (hr)	0.500 (0.167, 1.10)	0.667 (0.550, .983)	1.60 (1.10, 3.68)	0.667 (0.500, 0.983)	1.10 (0.467, 1.68)	3.57 (3.50, 3.68)
AUC_0-t (ng^.hr/mL)	25,500 ± 8980	472,000 ± 111,000	4760 ± 2790	10,600 ± 5010	25,200 ± 6870	13,000 ± 7060
M:P ratio	NA	12.5 ± 3.15	0.194 ± 0.079	0.514 ± 0.398	1.03 ± 0.451	0.579 ± 0.206

AUC_0-t area under the concentration time curve from time of administration to the last measurable concentration, estimated by the linear up/log down trapezoidal rule, C_max maximum plasma concentration, M:P metabolite:parent, PK pharmacokinetic(s), T_max time to C_max
^aMedian (range)

ISSN: 2162-3619